Actively Recruiting
Evaluating Pyridostigmine and Low-Dose Naltrexone for MECFS with Orthostatic Intolerance including Long COVID
Led by Brigham and Women's Hospital · Updated on 2026-10-15
160
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of Pyridostigmine Mestinon and Low-Dose Naltrexone LDN in adults aged 18 to 70 who meet the Canadian consensus criteria for Myalgic EncephalomyelitisChronic Fatigue Syndrome MECFS and have Orthostatic Intolerance OI. The study also includes participants with Long COVID if they meet the same criteria. This phase 2, double-blind, placebo-controlled trial aims to improve treatment options and understanding of this condition. Participants will be randomly assigned to one of four groups Pyridostigmine with LDN, Pyridostigmine with placebo, LDN with placebo, or double placebo. Pyridostigmine is taken as a liquid three times daily, with doses increasing from 20mg to 60mg per dose, while LDN is taken once daily, increasing from 1.5mg to 4.5mg. The study includes a scale-back plan to adjust dosages if participants experience intolerance, with weekly visits to manage this. During approximately three months of participation, individuals will attend three in-person visits and four virtual visits. Study procedures include two submaximal cardiopulmonary exercise tests, questionnaires completed virtually, and blood and urine collections. Researchers will measure functional capacity, oxygen uptake and utilization, heart rate recovery, symptom changes, pain levels, daily activity, heart rate variability, blood oxygen, resting heart rate, and cognitive reaction times. The overall trial is expected to take two years to complete.
CONDITIONS
Brief Title
LIFT: Life Improvement Trial
Research Team
R
Research Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here